Embecta Corp. specializes in the development, manufacturing, and sale of disposable medical products for diabetes management. Its core product portfolio includes insulin syringes, pen needles, and safety injection devices, which are distributed to wholesalers, pharmacies, and healthcare facilities in over 100 countries. The company also offers digital applications designed to assist patients in managing their condition. Originally the diabetes care division of Becton Dickinson (BD) with a history dating back to 1924, Embecta became an independent public company in 2022. It maintains a significant manufacturing footprint with facilities in the United States, Ireland, and China, producing approximately 8 billion injection devices annually.
